Rolland Carlson - WaferGen Bio-systems CEO and President and Director
CEO
Dr. Rolland Carlson, Ph.D. is President, Chief Executive Officer, Director of the Company. Dr. Carlson served as President and Director of Asuragen, Inc., a molecular diagnostic company specializing in personalized diagnostics, from April 2006 to May 2014. Dr. Carlson also served as Chief Executive Officer of Asuragen, Inc. from January 2013 to May 2014 and Chief Operating Officer of Asuragen, Inc. from January 2012 to December 2012. While at Asuragen, Inc., Dr. Carlson founded Mirna Therapeutics, a spinout of Asuragen, which has developed novel miRNAbased therapeutics currently in Phase I clinical trials for liver and other cancers. Prior to joining Asuragen, Dr. Carlson held several senior positions at Abbott Laboratories, including Vice President, Business Development Licensing, Global Medical Products and Vice President and Global General Manager of the Vysis, Inc., a whollyowned subsidiary of Abbott. Earlier in his career, Dr. Carlson was responsible for business development, licensing and strategic planning to establish new pharmaceutical and diagnostic platforms for the pediatric and womens health channels of the Ross Division of Abbott, and ran Abbotts global custom biopharmaceutical and specialty generics pharmaceutical business. Dr. Carlson has served on the board of directors of Pristine, Inc. since April 2015 since 2015.
| Age | 60 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Phone | 510-651-4450 |
| Web | http://www.wafergen.com |
WaferGen Bio-systems Management Efficiency
The company has return on total asset (ROA) of (90.11) % which means that it has lost $90.11 on every $100 spent on assets. This is way below average. WaferGen Bio-systems' management efficiency ratios could be used to measure how well WaferGen Bio-systems manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.94 M in liabilities with Debt to Equity (D/E) ratio of 0.8, which is about average as compared to similar companies. WaferGen Bio systems has a current ratio of 1.78, which is within standard range for the sector. Debt can assist WaferGen Bio-systems until it has trouble settling it off, either with new capital or with free cash flow. So, WaferGen Bio-systems' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like WaferGen Bio systems sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for WaferGen to invest in growth at high rates of return. When we think about WaferGen Bio-systems' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | CEO Age | ||
| Colin Fagen | QBE Insurance Group | 47 | |
| David Duclos | QBE Insurance Group | 56 | |
| Steven Johnston | Cincinnati Financial | 58 | |
| Katherine Antonello | Employers Holdings | 55 | |
| David Fried | QBE Insurance Group | 54 | |
| John Neal | QBE Insurance Group | 51 | |
| MA BA | NI Holdings | 58 | |
| Frederick III | Saia Inc | 56 | |
| Richard ODell | Saia Inc | 56 | |
| Joseph Puishys | Apogee Enterprises | 59 | |
| Ty Silberhorn | Apogee Enterprises | 56 | |
| Russell Johnston | QBE Insurance Group | 51 | |
| Douglas Dirks | Employers Holdings | 60 | |
| Vivek Bhatia | QBE Insurance Group | N/A | |
| Richard Pryce | QBE Insurance Group | 56 | |
Management Performance
| Return On Asset | -90.11 |
WaferGen Bio systems Leadership Team
Elected by the shareholders, the WaferGen Bio-systems' board of directors comprises two types of representatives: WaferGen Bio-systems inside directors who are chosen from within the company, and outside directors, selected externally and held independent of WaferGen. The board's role is to monitor WaferGen Bio-systems' management team and ensure that shareholders' interests are well served. WaferGen Bio-systems' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, WaferGen Bio-systems' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Makoto Kaneshiro, Independent Director | ||
| Robert Schueren, Director | ||
| Joel Kanter, Lead Independent Director | ||
| William McKenzie, Director | ||
| Michael Henighan, CFO, Secretary and Treasurer | ||
| Rolland Carlson, CEO and President and Director | ||
| Raymond Hautamaki, Independent Director | ||
| Ivan Trifunovich, Executive Chairman |
WaferGen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is WaferGen Bio-systems a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -90.11 | |||
| Profit Margin | (175.04) % | |||
| Operating Margin | (171.93) % | |||
| Current Valuation | 16.04 M | |||
| Shares Outstanding | 3.8 M | |||
| Shares Owned By Insiders | 19.50 % | |||
| Shares Owned By Institutions | 5.80 % | |||
| Number Of Shares Shorted | 240.41 K | |||
| Price To Earning | (1.16) X | |||
| Price To Book | 12.86 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards WaferGen Bio-systems in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, WaferGen Bio-systems' short interest history, or implied volatility extrapolated from WaferGen Bio-systems options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the WaferGen Bio systems information on this page should be used as a complementary analysis to other WaferGen Bio-systems' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in WaferGen Stock
If you are still planning to invest in WaferGen Bio systems check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the WaferGen Bio-systems' history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |